Dehen H, Dordain G, Doyon F
Presse Med. 1984 Jan 21;13(2):87-90.
A multicentre controlled trial was conducted on 383 patients to compare the effectiveness of flurbiprofen (100 mg/day) and an ergot derivative in preventing cerebral infarction. The end-point of the trial was recurrence within 3 years of treatment with one or the other drug of a fatal or non-fatal cerebral infarction. Only those patients who had already experienced an established and disabling ischaemic accident in the carotid or vertebro-basilar territory were included; 88% of these entered the trial less than 6 weeks after the accident. Sixty-one patients had recurrent cerebral infarction during the 3-year observation period: 22 in the flurbiprofen group and 39 in the ergot derivative group (p less than 0.02 log rank test adjusted by centre). The actuarial recurrence rates in the two groups were 13% and 21% respectively. These results concur with those of other trials involving aspirin to demonstrate the value of antiplatelet aggregation drugs in the secondary prevention of atherothrombotic cerebral infarction.
对383例患者进行了一项多中心对照试验，以比较氟比洛芬（100毫克/天）和一种麦角衍生物预防脑梗死的有效性。试验的终点是使用这两种药物之一治疗3年内发生致命或非致命性脑梗死的复发情况。仅纳入那些在颈动脉或椎基底动脉区域已发生明确且致残性缺血性事件的患者；其中88%在事件发生后不到6周进入试验。在3年观察期内，61例患者发生复发性脑梗死：氟比洛芬组22例，麦角衍生物组39例（经中心调整的对数秩检验，p<0.02）。两组的精算复发率分别为13%和21%。这些结果与其他涉及阿司匹林的试验结果一致，证明了抗血小板聚集药物在动脉粥样硬化血栓形成性脑梗死二级预防中的价值。
